Engilberto Ramos, MD
Family Medicine · Victoria, TXNPI 1508067885
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 28 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Johnson & Johnson accounts for 77.0% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2021 at $244 and has fallen 75.6% since, to $60 in 2025.
Across 28 payments — averaging $21.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$471
- Melinta Therapeutics, LLC$60
- AbbVie$30
- Merck$28
- Abbott$23
What the payments were for
- Food & beverage$612100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 22 | $471 |
| Melinta Therapeutics, LLC | 3 | $60 |
| AbbVie | 1 | $30 |
| Merck | 1 | $28 |
| Abbott | 1 | $23 |
How this compares
$612 in reported general payments places this provider in the 55th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 40 | $23,514 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 48 | $536 |
| Ondansetron OdtOndansetron | 15 | $527 |
| Potassium Chloride | 40 | $506 |
| Cefdinir | 27 | $469 |
| Pantoprazole Sodium | 71 | $442 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 45 | $442 |
| Flecainide Acetate | 23 | $394 |
| Nitroglycerin | 31 | $301 |
| Atorvastatin Calcium | 59 | $235 |
| Lactulose | 11 | $205 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $192 |
| Furosemide | 60 | $178 |
| Tamsulosin Hcl | 27 | $162 |
| ClopidogrelClopidogrel Bisulfate | 38 | $149 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Victoria
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
- Jose LedezmaEdinburg$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.